A carcinoid tumour presenting as Cushing's syndrome is reported. Although no tumour mass could be initially identified the patient returned with first a liver and subsequently a cerebellar mass both of which were resected. Only at post-mortem was the lung primary discovered. ACTH, gastrinreleasing peptide (GRP) and calcitonin gene-related peptide were elevated in plasma before resection of the hepatic tumour. These peptides were demonstrated in both the hepatic and cerebellar tumours by immunocytochemistry and radioimmunoassay. This case illustrates the occasional tendency of primary lung carcinoids to remain small and clinically undetectable while generating secondary tumours which are symptomatic. It is suggested that immunological demonstration of GRP may be diagnostically helpful in directing attention to the lung as a primary site in neuroendocrine tumours which present in this fashion.
Introduction
Gastrin-releasing peptide (GRP), a peptide of 27 amino acid residues,' and its C-terminal decapeptide2'3 (neuromedin C), are now considered to be the mammalian forms of bombesin. 4 Both amphibian bombesin and its mammalian counterparts have potent pharmacological effects in the gastrointestinal tract and the central nervous system. Infusion in man has shown that both bombesin and GRP release gastrointestinal and pancreatic hormones.5'6 Bombesin and GRP-like immunoreactivity have been reported in oat cell carcinoma of the bronchus7'8 where production of these peptides is frequently associated with calcitonin9'0 and ACTH.""2
Recently, a new peptide, 'calcitonin gene-related peptide' (CGRP), has been isolated. This 37 amino acid residue peptide is a product of mRNA formed by alternative tissue-specific RNA splicing after transcription of the calcitonin gene.'3 Human CGRP has been isolated from medullary carcinoma of the thyroid'4 and from a cell line derived from small cell carcinoma of the bronchus,'5 but its secretion from other neuroendocrine tumours has not previously been reported.
We report here a patient who presented with ectopic ACTH secretion syndrome resulting from a metastatic carcinoid tumour of pulmonary origin, which was found in addition to contain and secrete three forms of gastrin-releasing peptide (bombesin) and CGRP. 
Results

Radioimmunoassay ofplasma
Analysis of plasma samples taken prior to partial hepatectomy showed a raised level of ACTH at 539 ng/l, GRP 180 pmol/l (normally undetectable, i.e. <10pmol/l) and CGRP420pmol/l (normally undetectable, i.e.<20 pmol/l). After right hepatectomy plasma levels of ACTH fell to 63 ng/l while CGRP and GRP became undetectable.
Radioimmunoassay oftumour
Extracts from the tumour resected from the right hepatic lobe contained 2. V (GRP), while the second minor peak was co-eluted with C-terminal decapeptide of GRP (Kav 0.81) just after amphibian bombesin (Kav 0.78). Analysis of the tumour extracts on reverse phase HPLC revealed three major peaks of GRP-like immunoreactivity ( Figure  2) , in which only a proportion ofthe immunoreactivity had an identical retention time to that of C-terminal decapeptide of GRP (Figure 2) . Neither of the other two immunoreactive peaks corresponded to either pure synthetic porcine GRP or synthetic amphibian bombesin. Analysis of the tumour extracts on the gel column revealed two major CGRP immunoreactive peaks (Figure lc) . The earlier peak of Kav 0.17 was eluted between the dextran blue and cytochrome C, indicating a larger molecular form, whereas the second peak was co-eluted with synthetic human CGRP (Kav 0.37). In contrast, however, the pre-operative plasma contained only one major molecular form of CGRP-like immunoreactivity which emerged in the position of synthetic human CGRP (Figure ld) .
Histology oftumour tissue
The hepatic, cerebellar and pulmonary masses showed similar histological features. They were composed of ribbons, trabeculae, acini and irregular masses of Cushing's syndrome due to ectopic production of ACTH is a well recognized complication of neuroendocrine tumours, in particular small cell carcinoma of the bronchus. When tumor mass is small it may be the only manifestation and thus the presenting feature. Indeed the source of ACTH in this case eluded imaging techniques until 2 years after presentation when a hepatic mass and subsequently a posterior fossa deposit were detected. Nevertheless during life the tumour primary site remained unclear. Although primary neuroendocrine tumours of the liver have been reported,23 these are uncommon and at the present limit of resolution of imaging techniques the diagnosis may only be confidently made at postmortem when alternative more likely sites can be excluded. When this patient came to autopsy a small pulmonary nodule was discovered. We consider this to be the primary for several reasons. These include the relative frequency of bronchial carcinoids, the presence of cranial metastases (common in pulmonary tumours) and the histological demonstration that the tumour was present within a bronchus. Although a satisfactory retrospective diagnosis was possible, were there any other clues to the origin of the primary available during life?
Analysis of plasma and tumour extracts together with immunohistochemical examination of tissue sections suggested that three peptides were being synthesized and secreted by the carcinoid; ACTH, responsible for the Cushing's syndrome, gastrin-releasing peptide (GRP, bombesin) and calcitonin gene-related peptide (CGRP). In normal human tissues GRP-like immunoreactivity has been demonstrated predominantly in endocrine cells of the fetal and neonatal lung.24'2526 A number of common neoplasms also synthesize GRP, which occurs in two major molecular forms distinguishable by gel chromatography, small cell carcinoma of the bronchus,7'8'9'27'28 bronchial carcinoids29'30'3132 and medullary carcinoma of the thyroid.3236 A thyroid neoplasm is usually easily excluded clinically and therefore we suggest that GRP synthesis is a strong indicator ofpulmonary origin and should direct attention to the lung in cases such as this in which the primary site is obscure.
GRP is thought to have a number of biological effects including release of many gastrointestinal hormones. This may be demonstrated by infusion of GRP into healthy volunteers at lower levels than were present in this patient.5 6'37 Nevertheless no other gastrointestinal hormone was elevated in this case, a finding which is generally consistent with reports of patients with elevated plasma GRP immunoreactivities. The lack of stimulatory effect is unlikely to be due to the production of biologically inactive forms of the molecule as the antiserum used for radioimmunoassay reacts with the active site of GRP. It is conceivable, however, that chronic GRP secretion from a slowly developing tumour may be associated with down regulation of GRP receptors and consequent lack of effect. This is similar to the lack of effect of elevated plasma somatostatin concentrations in patients with somatostatinomas. 
